Nearly 50% of patients are treated with anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) and anti-programmed cell death protein 1 (PD-1) antibodies, leading to tumor regression and long-term long-lasting cancer control. Here, PDCD1 is linked to neoplasm.